NQF endorses two readmission measures

The National Quality Forum's (NQF) board of directors has endorsed two measures that address all-cause unplanned readmissions in hospitals.

“Almost one in five Medicare beneficiaries that leave a hospital end up being readmitted within 30 days,” said Janet Corrigan, PhD, MBA, president and CEO of NQF, in a statement. “Those readmissions cost about $15 billion annually, and many have the potential to be prevented. These new measures help push us as a nation to address this serious problem.”

Research shows an avoidable hospital readmission can mean prolonged illness, emotional distress and loss of productivity. Readmissions are attributable to a range of factors, NQF said, including the availability of social supports and post-acute care for people, especially those of low income, as they transition from the hospital back into the community.

The first measure endorsed, developed by the National Committee for Quality Assurance (NCQA), counts the number of inpatient stays for patients age 18 and older during a measurement year that were followed by an acute readmission for any diagnosis to any hospital within 30 days. It contrasts this count with a calculation of the predicted probability of an acute readmission. NCQA’s measure is intended for quality monitoring and accountability at the health plan level.

The second measure, co-developed by the Centers for Medicare & Medicaid Services (CMS) and researchers at Yale University in New Haven, Conn., estimates the risk-standardized rate of unplanned, all-cause readmissions to a hospital for any eligible condition within 30 days of hospital discharge for patients age 18 and older. The measure will result in a single summary risk-adjusted readmission rate for conditions or procedures that fall under five specialties: surgery/gynecology, general medicine, cardiorespiratory, cardiovascular and neurology. The CMS/Yale measure is specified for evaluating hospital performance.

NQF said it worked with both measure developers to assure that the two measures will be harmonized to ensure that the measures assess readmissions in a similar manner. For example, both measures will be aligned to remove the same set of planned readmissions.

In endorsing the CMS/Yale measure, the NQF board offered the following guidance to accompany the measure and help explain the multifaceted nature of hospital readmissions and the opportunity for broad stakeholder collaboration to help address the issue:

The endorsed measures are:
  • 1768: Plan all-cause readmissions (NCQA)
  • 1789: Hospital-wide all-cause readmission measure (CMS/Yale)

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.